Passive breath gating equipment for cone beam CT-guided RapidArc gastric cancer treatments

Hu, Weigang; Li, Guichao; Ye, Jinsong; Wang, Jiazhou; Peng, Jiayuan; Gong, Ming; Yu, Xiaoli; Studentski, Matthew T.; Xiao, Ying; Zhang, Zhen

doi:10.1016/j.radonc.2014.11.046

Cited by 2 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A novel technique that combines breath-hold, IGRT and VMAT was clinically implemented and showed both dosimetric benefit and delivery efficiency, 66 revealing a new trend based on the combination and integration of techniques.…”

Section: Interfractional Motionmentioning

confidence: 99%

Chemoradiation for gastric cancer: controversies, updates and novel techniques

Fan

Zhang

2015

BJR

View full text Add to dashboard Cite

The INT0116 trial established the role of adjuvant chemoradiation (CRT) in the multidisciplinary approach to the management of locally advanced gastric cancer. However, whether adjuvant CRT is indispensable for patients undergoing D2 dissection remains undefined. The adjuvant chemoradiation therapy in stomach cancer (ARTIST) trial, which was designed to compare adjuvant chemotherapy to CRT, failed to demonstrate differences in disease-free and overall survival in the whole study group; however, subgroup analysis indicated that patients with lymph node metastasis may benefit from additional radiation. A follow-up ARTIST II trial is currently under way. The efficacy of adjuvant CRT remains controversial because of variation among studies in the inclusion criteria and treatment delivery methods; however, the identification of patients who would benefit from CRT is critical. Advanced radiotherapy techniques such as intensity-modulated radiotherapy protect normal tissues via motion management and decreased radiation-induced toxicity and contribute to plan optimization. Further studies integrating clinical and molecular factors as well as neoadjuvant CRT are warranted.Gastric cancer is one of the most frequent malignancies. It is the fifth most common malignancy and the third leading cause of cancer-related death in the world.

show abstract

Section: Interfractional Motionmentioning

confidence: 99%